Kala Pharmaceuticals

General Information

We are a biopharmaceutical company focused on the development and commercialization of therapeutics using our proprietary nanoparticle-based Mucus Penetrating Particles, or MPP, technology, with an initial focus on the treatment of eye diseases. Our MPPs are selectively-sized nanoparticles and have proprietary coatings. We believe that these two key attributes enable even distribution of drug particles on mucosal surfaces and significantly increase drug delivery to target tissues by enhancing mobility of drug particles through mucus and preventing drug particles from becoming trapped and eliminated by mucus.

Employees: 25
Founded: 2009
Contact Information
Address 100 Beaver Street, Suite 201, Waltham, MA 02453, US
Phone Number (781) 996-5252
Web Address http://www.kalarx.com
View Prospectus: Kala Pharmaceuticals
Financial Information
Market Cap $349.2mil
Revenues $0 mil (last 12 months)
Net Income $-37.7 mil (last 12 months)
IPO Profile
Symbol KALA
Exchange NASDAQ
Shares (millions): 6.0
Price range $15.00 - $15.00
Est. $ Volume $90.0 mil
Manager / Joint Managers J.P. Morgan/ BofA Merrill Lynch
CO-Managers Wells Fargo Securities/ Wedbush PacGrow
Expected To Trade: 7/20/2017
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change